Dapagliflozin/Saxagliptin/Metformin hydrochloride

达格列净/沙格列汀/盐酸二甲双胍

Report date: 2022/01/21 20:00:34

Base Information

Drug NameDapagliflozin/Saxagliptin/Metformin hydrochloride
Drug Alias Name二甲双胍/达格列净/沙格列汀Saxagliptin/metformin/dapagliflozin达格列净+二甲双胍+沙格列汀Saxagliptin+metformin+dapagliflozin二甲双胍/沙格列汀/达格列净 +[17] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsSodium/glucose cotransporter 2 inhibitorsDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/05/02
Country/TerritoryUnited StatesEU
CombinationsYes Metformin HydrochlorideDapagliflozin Propanediol MonohydrateSaxagliptin Hydrate
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Ab
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeA10BD
Related LinksN/A